Immunogenicity and safety of mixed COVID-19 vaccine regimens in patients with immune-mediated inflammatory diseases: a single-centre prospective cohort study.

Carol A HitchonChristine MesaCharles N BernsteinKathryn C FitzgeraldCatherine CardSheila F O'BrienJohn Kim

Published in: BMJ open (2023)

Heterologous COVID-19 vaccination improves seroconversion rates following a vector vaccine and does not lead to IMID disease flare. IMIDs benefit from at least three vaccines.

Keyphrases

coronavirus disease
sars cov
oxidative stress
respiratory syndrome coronavirus